Atezolizumab, bevacizumab, pemetrexed and platinum for <i>EGFR</i>‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
The combination regimen yielded promising efficacy in NSCLC patients after EGFR-TKI resistance, particularly those with PD-L1-positive tumours. Higher peritumour NK cell and lower peripheral helper T cell were associated with favourable ORR and longer PFS, respectively. After disease progression, the proportion of S100A9<sup>+</sup> MDSC increased, but Treg cells decreased.
Authors
- Wei‐Yu Liao (ORCID: https://orcid.org/0000-0001-6383-3470)
- Kah Yi Yap
- Chong‐Jen Yu (ORCID: https://orcid.org/0000-0001-5664-9392)
- Shang‐Gin Wu (ORCID: https://orcid.org/0000-0001-8889-689X)
- Jin‐Yuan Shih (ORCID: https://orcid.org/0000-0002-2854-5067)
- Ya‐Ting Chuang
- James Chih‐Hsin Yang (ORCID: https://orcid.org/0000-0002-5586-5138)
- Shu‐Chin Lin (ORCID: https://orcid.org/0000-0002-7652-7306)
- Chao‐Chi Ho
- Weng Si Kou
- Ching‐Yao Yang (ORCID: https://orcid.org/0000-0003-4927-4814)
- Shu‐Han Yu (ORCID: https://orcid.org/0000-0002-0351-6999)
- Kuang Lin (ORCID: https://orcid.org/0000-0003-3017-6026)
- Bin‐Chi Liao
- Yen‐Ting Lin
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Health Research Institutes (TW)
- National Taiwan University (TW)
- National Taiwan University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1002/ctm2.70149
- Citations
- 9
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- F. Hoffmann-La Roche
- Ministry of Health and Welfare
- National Taiwan University Hospital
- National Taiwan University
- National Science and Technology Council